Evidence map›Paper›PMID 37803101›Full record

Trial reportScientific reports2023

Effects of a lotion containing probiotic ferment lysate as the main functional ingredient on enhancing skin barrier: a randomized, self-control study.

Hongchang Cui, Congrui Feng, Tao Zhang, Verónica Martínez-Ríos, Patricia Martorell, Marta Tortajada, Sidao Cheng, Shumin Cheng, Zhi Duan

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Oral Probiotics inMedicina (Kaunas, Lithuania) · 2025
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Skin Deep: The Potential of Microbiome Cosmetics.Journal of microbiology (Seoul, Korea) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Hongchang CuiQingdao Vland Biotech Co., Ltd., 596-1 Jiushui East Road, Laoshan District, Qingdao, 266102, China.
Congrui FengQingdao Vland Biotech Co., Ltd., 596-1 Jiushui East Road, Laoshan District, Qingdao, 266102, China.
Tao ZhangQingdao Vland Biotech Co., Ltd., 596-1 Jiushui East Road, Laoshan District, Qingdao, 266102, China.
Verónica Martínez-RíosADM, Nutrition, Health and Wellness, Biopolis S.L., Parc Científic Universitat de València, C/ Catedrático Agustín Escardino Benlloch, 9, 46980, Paterna, Spain.
Patricia MartorellADM, Nutrition, Health and Wellness, Biopolis S.L., Parc Científic Universitat de València, C/ Catedrático Agustín Escardino Benlloch, 9, 46980, Paterna, Spain.
Marta TortajadaADM, Nutrition, Health and Wellness, Biopolis S.L., Parc Científic Universitat de València, C/ Catedrático Agustín Escardino Benlloch, 9, 46980, Paterna, Spain.
Sidao ChengQingdao Vland Biotech Co., Ltd., 596-1 Jiushui East Road, Laoshan District, Qingdao, 266102, China.
Shumin ChengQingdao Vland Biotech Co., Ltd., 596-1 Jiushui East Road, Laoshan District, Qingdao, 266102, China.
Zhi DuanQingdao Vland Biotech Co., Ltd., 596-1 Jiushui East Road, Laoshan District, Qingdao, 266102, China. duanzhi@vlandgroup.com.
Sansure Biotech (China) · CNBiopolis (Spain) · ESUniversitat de València · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is an emergent need to develop functional cosmetic ingredients for the topical management of skin barrier function. This study aimed to investigate the efficacy of a lotion containing fermented lysates VHProbi® Mix R for enhancing the skin barrier. In vitro studies demonstrated that fermented cultures of both Lacticaseibacillus rhamnosus VHProbi® E06 (E06) and L. paracasei VHProbi® E12 (E12) had antioxidant capacity, showing promising scavenging capability for 2,2-diphenyl-1-picryl-hydrazyl. The antioxidant capacity of these strains was also demonstrated in the model of Caenorhabditis elegans. In addition, the fermented lysates of both E06 and E12 enhanced the proliferation of HaCaT cells and ameliorated the toxicity induced by Staphylococcus aureus ATCC 25923, hydrogen peroxide, and ultraviolet B radiation in the HaCaT cell models, which simulated the irritants that facial sensitive skin is exposed to. Subsequently, the ingredient VHProbi® Mix R was formulated using four kinds of fermented lysates: E06, E12, Lactiplantibacillus plantarum VHProbi® E15, and Lactobacillus helveticus VHProbi® Y21. A clinical study was conducted to investigate whether a lotion containing VHProbi® Mix R would be beneficial for people to enhance skin barrier. The participants were asked to use the investigational product for 30 days. Several indicators, including transepidermal water loss (TEWL), skin moisturization, and redness were measured at day 0 and day 30 using VISIA®-CR and CK®-MPA systems. Meanwhile, the burden of sensitive skin (BoSS) and self-assessment questionnaires were performed at baseline and endpoint of this study. The study data showed that at day 30, there was a significant decrease in TEWL (P < 0.01), redness measured by CK®-MPA (P < 0.01), and redness profile measured by VISIA®-CR compared with the baseline measurements. Skin moisturization had significantly increased after treatment with the lotion for 30 days. BoSS and self-assessment questionnaires also substantiated that the participants felt a markedly positive change in their sensitive skin. Hence, we hypothesize that applying the topical functional VHProbi® Mix R could confer effective benefits for people with sensitive skin and this represents a promising intervention for enhancing skin barrier.

Indexed as

Dermatologic AgentsProbioticsAntioxidantsEmollientsFibrinolytic AgentsHumansSkinWaterAntioxidantsDermatologic AgentsEmollientsFibrinolytic AgentsWater

Identifiers

PMID37803101
PMCPMC10558477
OpenAlexW4387409368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.